Program
alpha 1-Antitrypsin
Also written as “Alpha-1 MP”, “GLASSIA” and “Alpha1-proteinase inhibitor”.
Its studies are mostly in alpha 1-Antitrypsin Deficiency · Pulmonary Disease, Chronic Obstructive · Pulmonary Emphysema · Graft vs Host Disease · Diabetes Mellitus, Type 1, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grifols | 131 open or running | phase 3since Feb 20, 2006 | Sep 12, 2005 | Sep 2028phase 3 · NCT02796937 |
| Takeda | 70 open or running | phase 4since Nov 3, 2006 | Nov 3, 2006 | none ahead |
| CSL | 31 open or running | phase 4since Dec 2, 2005 | Dec 2, 2005 | Sep 15, 2033phase 4 · NCT07326592 |
| Kamada | 30 open or running | phase 3since Dec 17, 2019 | Feb 24, 2011 | none ahead |
Also a collaborator on its studies: baxalta-innovations-gmbh-now-part-of-shire.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Sep 12, 2005.
- Nov 27, 2013Phase 2 study in Diabetes MellitusKamada · NCT02005848 · 70 enrolled · Israel
- Mar 11, 2014Phase 2 study in Diabetes Mellitus, Type 1Grifols · NCT02093221 · 76 enrolled · United States
- Oct 31, 2014Phase 3 study in Alpha₁-Antitrypsin DeficiencyGrifols · NCT02282527 · 32 enrolled · United States
- Aug 14, 2015Phase 3 study in alpha 1-Antitrypsin DeficiencyTakeda · NCT02525861 · 34 enrolled · United States, Canada
- Mar 23, 2016Phase 3 study in Pulmonary Disease, Chronic ObstructiveTakeda · NCT02722304 · 7 enrolled · United States, Australia, Canada
- Jun 3, 2016Phase 3 study in Pulmonary EmphysemaGrifols · NCT02796937 · 290 planned · United States, Australia, Canada and more
- Aug 12, 20162 phase 2 studies in alpha 1-Antitrypsin DeficiencyGrifols · NCT02870348, NCT02870309
- Oct 24, 2016Phase 3 study in Graft vs Host DiseaseTakeda · NCT02956122 · 1 enrolled · United States
- Nov 15, 2019Phase 3 study in Graft vs Host DiseaseCSL · NCT04167514 · 136 enrolled · United States
- Dec 17, 2019Phase 3 study in alpha 1-Antitrypsin DeficiencyKamada · NCT04204252 · 98 enrolled · Belgium, Finland, Ireland and more
- Jun 17, 2020Phase 4 study in Pulmonary Disease, Chronic ObstructiveTakeda · NCT04440488
- Jul 28, 2020Phase 2 study in COVID-19Grifols · NCT04495101 · 100 enrolled · Spain
- Jun 17, 2022Phase 4 study in Pulmonary Disease, Chronic ObstructiveTakeda · NCT05466747
- Jan 7, 2026Phase 4 study in alpha 1-Antitrypsin DeficiencyCSL · NCT07326592 · 270 planned · Denmark
Ahead
- Sep 2028Primary completion: phase 3 study in Pulmonary EmphysemaGrifols · NCT02796937
- Sep 15, 2033Primary completion: phase 4 study in alpha 1-Antitrypsin DeficiencyCSL · NCT07326592
TargetBeta
“Leukocyte elastase inhibitor”ChEMBL 37, by rule
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07326592alpha 1-Antitrypsin Deficiency · Denmark | 4 | Recruiting | CSL | Sep 15, 2033 | 270 |
| NCT05466747Pulmonary Disease, Chronic Obstructive | 4 | Withdrawn | Takeda | Apr 26, 2027 | 0 |
| NCT04495101COVID-19 · Spain | 2 | Completed | Grifols | Apr 26, 2021 | 100 |
| NCT04440488Pulmonary Disease, Chronic Obstructive | 4 | Withdrawn | Takeda | Sep 12, 2025 | 0 |
| NCT04204252alpha 1-Antitrypsin Deficiency · Belgium, Finland, Ireland and more | 3 | Terminated | Kamada | Feb 19, 2026 | 98 |
| NCT04167514Graft vs Host Disease · United States | 3 | Completed | CSL | Sep 11, 2023 | 136 |
| NCT02956122Graft vs Host Disease · United States | 3 | Terminated | Takeda | May 3, 2018 | 1 |
| NCT02870348alpha 1-Antitrypsin Deficiency · Japan | 2 | Completed | Grifols | Feb 16, 2021 | 4 |
| NCT02870309alpha 1-Antitrypsin Deficiency · Japan | 2 | Completed | Grifols | Mar 15, 2017 | 4 |
| NCT02796937Pulmonary Emphysema · United States, Australia, Canada and more | 3 | By invitation | Grifols | Sep 2028 | 290 |
| NCT02722304Pulmonary Disease, Chronic Obstructive · United States, Australia, Canada | 3 | Terminated | Takeda | Sep 14, 2018 | 7 |
| NCT02525861alpha 1-Antitrypsin Deficiency · United States, Canada | 3 | Completed | Takeda | Jul 29, 2020 | 34 |
| NCT02282527Alpha₁-Antitrypsin Deficiency · United States | 3 | Completed | Grifols | Jan 2016 | 32 |
| NCT02093221Diabetes Mellitus, Type 1 · United States | 2 | Terminated | Grifols | Jan 2017 | 76 |
| NCT02005848Diabetes Mellitus · Israel | 2 | Completed | Kamada | Feb 2017 | 70 |
| NCT01983241Pulmonary Emphysema · United States, Argentina, Australia and more | 3 | Completed | Grifols | Jul 7, 2026 | 345 |
| NCT01684410Cystic Fibrosis · United States | 2 | Completed | Grifols | Oct 2013 | 30 |
| NCT01651351alpha 1-Antitrypsin Deficiency · United States | 4 | Completed | Takeda | Jan 16, 2013 | 30 |
| NCT01304537Diabetes Mellitus, Type 1 · Israel | 2 | Completed | Kamada | Nov 2012 | 24 |
| NCT01213043Emphysema · United States | 2 | Completed | Grifols | Jan 2012 | 30 |
| NCT00486837Cystic Fibrosis | 2 | Completed | Grifols | Jun 2004 | 72 |
| NCT00396006alpha 1-Antitrypsin Deficiency · Australia, New Zealand | 4 | Completed | Takeda | Dec 14, 2007 | 21 |
| NCT00301366alpha 1-Antitrypsin Deficiency · United States, United Kingdom | 3 | Completed | Grifols | Mar 2007 | 38 |
| NCT00295061alpha 1-Antitrypsin Deficiency · United States | 3 | Completed | Grifols | Feb 2007 | 24 |
| NCT00261833alpha 1-Antitrypsin Deficiency · United States, Australia, Canada and more | 4 | Completed | CSL | Sep 2012 | 180 |
| NCT00263887alpha 1-Antitrypsin Deficiency · Denmark, Sweden, United Kingdom | 2 | Completed | Grifols | Jan 2007 | 77 |
How it is read
Names in the registry
- “Alpha-1 MP”, 5 entries
- “GLASSIA”, 2 entries
- “Alpha1-proteinase inhibitor”, 2 entries
- “Alpha1-Proteinase Inhibitor (Human)”, 2 entries
- “CE1226”, 1 entry
Conditions, from the studies’ own filings
- alpha 1-Antitrypsin Deficiency, 12 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Pulmonary Emphysema, 2 studies
- Graft vs Host Disease, 2 studies
- Diabetes Mellitus, Type 1, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.